< Back to all clusters
[HEALTH] · United States · 7 sources

started · updated

FDA Advisory Panel Approves Six Peptides for Compounding Use

The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted to recommend six of seven peptide compounds for addition to the 503A Bulks List, which would allow licensed compounding pharmacies to prepare them for patients with a prescription. Approved peptides include BPC‑157 (for ulcerative colitis), MOTS‑c (for obesity and osteoporosis), KPV, TB‑500, semax and epitalon. The only compound that failed to clear the panel was emideltide, which lost by a single vote. Vote margins were narrow—reported as 8‑6 for some compounds and 7‑5 for others. The advisory panel, whose members were largely appointed by HHS Secretary Robert F. Kennedy Jr., included several doctors and pharmacists with financial ties to the peptide industry. FDA staff warned that the scientific evidence does not meet the agency’s safety and efficacy standards, and their recommendation is not binding; a final FDA decision will be issued after a public comment period. The vote reflects growing pressure from wellness influencers and “biohacking” communities to broaden access to these unproven substances.

Entities

BPC-157 · MOTS‑c · Pharmacy Compounding Advisory Committee · Robert F. Kennedy Jr. · U.S. Food and Drug Administration (FDA)

Claims

What the coverage asserts, and how many sources carry each claim.